February 2026 continued the strong funding momentum we saw in January, with capital flowing into digital therapeutics, hospital-focused AI, drug discovery platforms, telepsychiatry, and medical imaging.
From early-stage AI startups to late-stage telehealth leaders, investors doubled down on companies solving clinical efficiency gaps, expanding access, and accelerating drug development.
Here’s a snapshot of the major funding announcements from the month.
Talkiatry
Funds raised: $210.0M
Round: Series D
Investors: Perceptive Advisors (lead), Sofina, Andreessen Horowitz, blisce/, Left Lane Capital, Banc of California
About: U.S.-based telepsychiatry platform connecting patients to in-network psychiatrists for virtual mental healthcare.
How it plans to use the funds: Scale its national psychiatrist network, expand payer partnerships, and deepen access to virtual mental healthcare.
Temple
Funds raised: $54.0M
Round: Seed
Investors: Steadview Capital, Peak XV Partners, Info Edge Ventures, Dharana Capital, and 90+ investors including employee participants
About: Brain-focused wearable startup building devices designed to measure cerebral blood flow and generate neurological performance insights.
How it plans to use the funds: Accelerate R&D, expand engineering teams, and move toward commercial launch of its first wearable product.
Anterior
Funds raised: $40.0M
Round: Series B
Investors: Sequoia Capital, FPV Ventures, Kinnevik AB, New Enterprise Associates
About: AI-powered hospital administration platform modernizing revenue cycle and back-office workflows.
How it plans to use the funds: Scale enterprise deployments and expand AI automation capabilities.
Turbine
Funds raised: $25.0M
Round: Series B
Investors: Interactive Venture Partners (lead), OSCAR&PAUL Beiersdorf VC, Accel, MSD, Mercia Ventures
About: AI-driven drug discovery company modeling disease biology to identify and validate novel drug targets.
How it plans to use the funds: Advance therapeutic programs and expand pharma collaborations.
Big Health
Funds raised: $23.7M
Round: Series D
Investors: .406 Ventures, AlleyCorp; participation from CVS Health Ventures, Blue Venture Fund, Sandbox Clinical Ventures, Gilde Healthcare, Supermoon Capital
About: Prescription digital therapeutics company focused on insomnia and anxiety treatment.
How it plans to use the funds: Expand payer coverage and increase clinical adoption of its PDT solutions.
nyra health
Funds raised: $20.0M
Round: Series A
Investors: Armira Growth, Wellington Partners, Crane Venture Partners, EVER Pharma
About: Digital therapeutics company developing clinically validated neurorehabilitation solutions.
How it plans to use the funds: Expand commercial footprint and advance product innovation.
OncoRes Medical
Funds raised: $19.0M
Round: Series B
Investors: Brandon Capital Partners, Radar Ventures, Morgans, The Table Club
About: Medical imaging company developing advanced cancer surgery imaging tools.
How it plans to use the funds: Drive regulatory approvals and expand commercialization efforts.
Lifeaz
Funds raised: $15.4M
Round: Series B
Investors: Mutuelles Impact, BNP Paribas, Mirova, GO Capital
About: Consumer healthtech building connected emergency response devices and CPR education tools.
How it plans to use the funds: Expand across European markets and scale distribution.
Pharmacelera
Funds raised: $7.1M
Round: Series A1
Investors: Heran Partners (lead), Inveready, Clave Capital, Bio&Tech Smart Capital
About: AI-powered molecular design platform accelerating drug discovery.
How it plans to use the funds: Expand R&D capabilities and pharma collaborations.
Vuno
Funds raised: $6.9M
Round: Strategic
Investor: Pathway Investment
About: AI medical imaging company building diagnostic support tools across radiology and cardiology.
How it plans to use the funds: Strengthen AI portfolio and expand partnerships.
Neupulse
Funds raised: $3.6M
Round: Seed
Investors: EoS Advisory, Midlands Engine Investment Fund II
About: Wearable neurotechnology company developing non-invasive rehabilitation devices.
How it plans to use the funds: Clinical validation and commercialization.
Oncare
Funds raised: $3.0M
Round: Series A
Investors: Sky Impact Capital (lead), Huddle Ventures, Lotus Herbal Group, SteerX, Tremis Capital
About: Disease management platform building structured chronic care pathways.
How it plans to use the funds: Expand programs and strengthen care delivery infrastructure.
Helia Care
Funds raised: $3.0M
Round: Seed
Investors: In Revenue Capital, Habanero Ventures
About: Early-stage healthtech startup focused on care enablement solutions.
How it plans to use the funds: Product development and go-to-market expansion.
M&A Activity in February 2026
Eucalyptus
Acquired by: Hims & Hers
Deal value: $1.6B
Major telehealth consolidation play strengthening cross-border digital care expansion.
Faeth Therapeutics
Acquired by: Sensei Biotherapeutics
Oncology-focused metabolic therapeutics company joining to strengthen cancer pipeline development.
Wrapping up
February’s funding activity shows:
- Large checks continue flowing into mental health and telepsychiatry
- AI-driven hospital admin and imaging platforms are scaling fast
- Drug discovery remains a strong venture magnet
- Wearables are evolving beyond fitness into neurological insight
Momentum remains strong heading into Q2.
